GSK241213P36000
- 2.20
- +0.28+14.58%
GlaxoSmithKline Newsroom
Barclays Remains a Hold on GlaxoSmithKline (GSK)
TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $45
Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Deutsche Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Goldman Sachs Keeps Their Hold Rating on GlaxoSmithKline (GSK)
J.P. Morgan Remains a Sell on GlaxoSmithKline (GSK)
Berenberg Lowers Price Target on GSK to GBP16 From GBP18.20, Maintains Buy Rating
Berenberg Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
Optimistic Buy Rating for GlaxoSmithKline: Undervalued Stock With Promising Growth Prospects
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
GSK Cut to Hold From Buy by Deutsche Bank
GSK Target Cut to GBP13.50 From GBP17.00 by Deutsche Bank
GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
GSK Analyst Ratings
GSK Target Cut to 1,525p From 2,000p by Jefferies
Jefferies Downgrades GlaxoSmithKline(GSK.US) to Hold Rating, Cuts Target Price to $39.5
GlaxoSmithKline (GSK) Was Downgraded to a Hold Rating at Jefferies
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
GSK Cut to Neutral From Buy by Guggenheim
GSK Analyst Ratings